M1774
Phase 2Small molecule
EMD Serono Research & Development Institute, Inc.M1774 is one of 68 small molecule programs targeting Breast Cancer. It is currently in Phase 2.
2
Indications
4
Total Trials
4
Active Trials
67
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tykerb
GSKPreclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
M1774
EMD Serono Research & Development Institute, Inc.Phase 2
Acupan
YYonsei University
Preclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Paracetamol
GSKPreclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic or Locally Advanced Unresectable Solid Tumors1 trial
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
Active, not recruiting·EMD Serono Research & Development Institute, Inc.·Phase 1·NCT04170153·161 enrolled
EMD Serono Research & Development Institute, Inc.·Phase 1·NCT04170153·161 enrolledBreast Cancer1 trial
Endometrial Cancer1 trial
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
Recruiting·—·Phase 2·NCT06518564·25 enrolled
Non-squamous NSCLC1 trial
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
Active, not recruiting·EMD Serono Research & Development Institute, Inc.·Phase 1/2·NCT05882734·61 enrolled
EMD Serono Research & Development Institute, Inc.·Phase 1/2·NCT05882734·61 enrolledSources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for M1774. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details